Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | UBE2T | Q9NPD8 | 1/20 | 0.58 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.58 |
| ▸ | HTR1A | P08908 | 7/20 | 0.56 |
| ▸ | HTR7 | P34969 | 7/20 | 0.56 |
| ▸ | DRD2 | P14416 | 6/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.56 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 5/20 | 0.50 |
| ▸ | HTR2A | P28223 | 5/20 | 0.50 |
| ▸ | HTR2C | P28335 | 4/20 | 0.50 |
| ▸ | HRH1 | P35367 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5537342 | 0.95 | SMN1; SMN2 (0.60) | SMN1; SMN2ALOX15HTTUBE2TASIC3 | |
| SCHEMBL5543152 | 0.93 | SMN1; SMN2 (0.59) | SMN1; SMN2ALOX15HTTUBE2TASIC3 | |
| SCHEMBL8904885 | 0.89 | UBE2T (0.61) | SMN1; SMN2ALOX15HTTUBE2TASIC3 | |
| SCHEMBL9641726 | 0.89 | SMN1; SMN2 (0.70) | SMN1; SMN2ALOX15HTTUBE2TASIC3 | |
| Bromide SCHEMBL11522514 | 0.85 | SMN1; SMN2 (0.66) | SMN1; SMN2ALOX15HTTUBE2TASIC3 | |
| SCHEMBL19372016 | 0.85 | UBE2T (0.70) | SMN1; SMN2ALOX15HTTUBE2TASIC3 | |
| SCHEMBL14835424 | 0.82 | SMN1; SMN2 (0.67) | SMN1; SMN2ALOX15HTTUBE2TASIC3 | |
| SCHEMBL14834856 | 0.82 | SMN1; SMN2 (0.62) | SMN1; SMN2ALOX15HTTUBE2TASIC3 | |
| SCHEMBL20358330 | 0.82 | SMN1; SMN2 (0.62) | SMN1; SMN2ALOX15HTTUBE2TASIC3 | |
| SCHEMBL10763327 | 0.82 | UBE2T (0.68) | SMN1; SMN2ALOX15HTTUBE2TASIC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| CN-101384532-B | method for producing optically active alcohol | KOTOBUKI PHARMACEUTICAL CO LTD | 2013-01-02 | — | — | CN | disclosed |
| US-7956182-B2 | Process for preparing optically active alcohols | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2011-06-07 | — | — | US | disclosed |
| CN-101384532-A | Method for producing optically active alcohol | KOTOBUKI PHARMACEUTICAL CO LTD (JP) | 2009-03-11 | — | — | CN | disclosed |
| US-20090062527-A1 | Process for Preparing Optically Active Alcohols | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1988071-A1 | METHOD OF PRODUCING OPTICALLY ACTIVE ALCOHOL | Kotobuki Pharmaceutical Co., Ltd. (JP) | 2008-11-05 | — | — | EP | disclosed |
| CN-101255170-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-09-03 | — | — | CN | disclosed |
| CN-101172981-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-05-07 | — | — | CN | disclosed |
| CN-100366624-C | 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds | OTSUKA PHARMA CO LTD (JP) | 2008-02-06 | — | — | CN | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | SMN1; SMN2 3985/4885ALOX15 2847/4885HTT 4644/4885 |
| US-20090062527-A1 | Process for Preparing Optically Active Alcohols | ADH1C, ADH1A, ADH5 | SMN1; SMN2 2625/4885ALOX15 2506/4885HTT 3013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.